700 related articles for article (PubMed ID: 25893588)
1. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.
Williams C; Brunskill S; Altman D; Briggs A; Campbell H; Clarke M; Glanville J; Gray A; Harris A; Johnston K; Lodge M
Health Technol Assess; 2006 Sep; 10(34):iii-iv, ix-xi, 1-204. PubMed ID: 16959170
[TBL] [Abstract][Full Text] [Related]
3. ErbB2+ metastatic breast cancer treatment after progression on trastuzumab: a cost-effectiveness analysis for a developing country.
Chicaíza-Becerra L; García-Molina M; Gamboa O; Castañeda-Orjuela C
Rev Salud Publica (Bogota); 2014; 16(2):270-80. PubMed ID: 25383500
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews.
Diaby V; Almutairi RD; Babcock A; Moussa RK; Ali A
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):353-364. PubMed ID: 33213205
[No Abstract] [Full Text] [Related]
5. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
Gogate A; Rotter JS; Trogdon JG; Meng K; Baggett CD; Reeder-Hayes KE; Wheeler SB
Breast Cancer Res Treat; 2019 Apr; 174(2):343-355. PubMed ID: 30603995
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
Chan AL; Leung HW; Lu CL; Lin SJ
Ann Pharmacother; 2009 Feb; 43(2):296-303. PubMed ID: 19193576
[TBL] [Abstract][Full Text] [Related]
8. Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer.
Pouwels XGLV; Ramaekers BLT; Joore MA
Breast Cancer Res Treat; 2017 Oct; 165(3):485-498. PubMed ID: 28689361
[TBL] [Abstract][Full Text] [Related]
9. Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review.
Poonawalla IB; Parikh RC; Du XL; VonVille HM; Lairson DR
Pharmacoeconomics; 2015 Nov; 33(11):1155-85. PubMed ID: 26072142
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of vinorelbine alone or vinorelbine plus cisplatin for stage IV NSCLC.
Evans WK
Oncology (Williston Park); 1998 Mar; 12(3 Suppl 4):18-25; discussion 25-6. PubMed ID: 9556779
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of docetaxel for breast cancer.
Lwin Z; Leighl N
Expert Opin Pharmacother; 2009 Feb; 10(2):283-90. PubMed ID: 19236199
[TBL] [Abstract][Full Text] [Related]
12. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
13. Is adjuvant therapy for older patients with node (+) early breast cancer cost-effective?
Naeim A; Keeler EB
Breast Cancer Res Treat; 2005 Nov; 94(2):95-103. PubMed ID: 16261407
[TBL] [Abstract][Full Text] [Related]
14. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Durkee BY; Qian Y; Pollom EL; King MT; Dudley SA; Shaffer JL; Chang DT; Gibbs IC; Goldhaber-Fiebert JD; Horst KC
J Clin Oncol; 2016 Mar; 34(9):902-9. PubMed ID: 26351332
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives.
Diaby V; Ali AA; Williams KJ; Ezendu K; Soto-Perez-de-Celis E; Chavarri-Guerra Y; de Lima Lopes G
Breast Cancer Res Treat; 2017 Dec; 166(3):951-963. PubMed ID: 28840424
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
Wolowacz SE; Cameron DA; Tate HC; Bagust A
J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
[TBL] [Abstract][Full Text] [Related]
18. Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
Cortés J; Dieras V; Ro J; Barriere J; Bachelot T; Hurvitz S; Le Rhun E; Espié M; Kim SB; Schneeweiss A; Sohn JH; Nabholtz JM; Kellokumpu-Lehtinen PL; Taguchi J; Piacentini F; Ciruelos E; Bono P; Ould-Kaci M; Roux F; Joensuu H
Lancet Oncol; 2015 Dec; 16(16):1700-10. PubMed ID: 26596672
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer.
Garrison LP; Lubeck D; Lalla D; Paton V; Dueck A; Perez EA
Cancer; 2007 Aug; 110(3):489-98. PubMed ID: 17592827
[TBL] [Abstract][Full Text] [Related]
20. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
